BIG Breast International Group
We will find a cure for breast cancer through global research and collaboration.

BIG 3-02 TEXT

The Tamoxifen and EXemestane Trial (TEXT) is a phase III trial evaluating the role of exemestane plus GnRH analogue as adjuvant therapy for premenopausal women with endocrine responsive breast cancer.

Coordinating group: IBCSG

Patients accrual
Recruitment to TEXT was suspended on 30 November 2007 because the originally planned target accrual had been reached. According to the study amendment 2, the recruitment has been reopened in November 2008 to accrue another 600 patients.

Start date: August 2003
Target nr. of patients: 1845
Closure date: November 2007
Accrual at 30 November 2007: 2039

New target nr. of patients: 2639
Date of closure: March 2011
Final accrual: 2639

ClinicalTrials.gov Identifier: NCT00963417

To learn more, visit: http://www.ibcsg.org/Public/Health_Professionals/Closed_Trials/IBCSG_25-02/Pages/IBCSG25-02BIG3-02%28TEXT%29.aspx

Scroll to top

Contact us

Breast International Group (BIG)-aisbl Blvd de Waterloo 121 B-1000 Brussels | Belgium VAT BE 0468 176 240